Sartorius reports nine-month growth: Sartorius stock gains 5.21 percent

Published on 10/22/2026 at 09:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius stock trades at EUR 274.70 on October 22, 2026, 5.21 percent above the Xetra close. Nine-month revenue reached EUR 2.74 billion.

Nine-month performance sets the tone

Sartorius reported EUR 2.74 billion in nine-month revenue on October 22, 2026.
The operating EBITDA margin reached 30.2 percent in the first nine months of 2026, up from 29.7 percent.
Sartorius stock trades at EUR 274.70 at 9:45 a.m. CEST at Lang & Schwarz on October 22, 2026, 5.21 percent above the Xetra close of October 21, 2026.
UBS kept its EUR 300.00 target and Buy rating in its October 14, 2026 research note.
Full-year 2026 figures are scheduled for February 23, 2027.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius (ISIN DE0007165631) was trading at EUR 274.70 at Lang & Schwarz on October 22, 2026 at 9:45 a.m. CEST, 5.21 percent above the Xetra close of October 21, 2026 at EUR 261.10. The company reported EUR 2.74 billion in revenue for the first nine months of 2026, according to TradingView on October 22, 2026.

Revenue growth reaches 4.90 percent

Reported group revenue rose 4.90 percent from the prior-year period to EUR 2.74 billion. Operational revenue excluding customer compensation for U.S. tariffs grew 8.10 percent in constant currencies, giving investors a clearer view of underlying demand. Sartorius said recurring consumables remained the main growth driver, while demand for bioprocess equipment and laboratory instruments continued to recover.

Underlying EBITDA increased 6.90 percent to EUR 828.00 million in the first nine months of 2026. The margin rose to 30.20 percent from 29.70 percent, while the company reported underlying net profit of EUR 260.00 million, up 6.70 percent from EUR 244.00 million.

What does 30.20 percent mean?

The margin improvement supports Sartorius's confirmed 2026 outlook. Management expects constant-currency group revenue growth of 5 to 9 percent before tariff effects and an operating EBITDA margin slightly above 30 percent. The Lab Products & Services division is now expected to reach the upper end of its 4 to 6 percent growth range, while its margin is projected to be slightly above 21 percent.

Three dated signals for investors

On October 12, 2026, JPMorgan kept its Overweight rating and EUR 295.00 target for Sartorius, according to Finanznachrichten. On October 15, 2026, UBS retained its Buy rating and EUR 300.00 target, with tariff costs identified as a risk in the research note published by T Online. The October 22, 2026 results are the third dated signal and carry the latest operating figures.

Upcoming reporting dates

The next two scheduled dates are the full-year 2026 figures on February 23, 2027 and the annual general meeting on April 15, 2027, both listed in the company's financial calendar carried by TradingView.

Stock trades above the close

Sartorius stock was trading at EUR 274.70 at Lang & Schwarz on October 22, 2026 at 9:45 a.m. CEST, 5.21 percent above the Xetra close of October 21, 2026 at EUR 261.10. The quote sits within the EUR 198.50 to EUR 276.70 52-week range, while market capitalization stood at EUR 17.2 billion as of October 22, 2026. The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.